- Home
- Therapeutics
- Oncology
- Early Phase Oncology
Early phase oncology
Operational and clinical development expertise for early phase oncology assets
Optimise study design for the success of your early phase oncology asset
Empower and streamline your clinical development programme by applying transformative changes. ICON’s clinical and operational expertise in the clinical development of early phase oncology assets are founded on successful principles, with on-demand access to critical and supportive resources tailored to early phase oncology trials, enabling:
Optimised study design
Fully functional adaptive trials, enabling smarter decision making and overall trial efficiency, are a reality with ICON’s methodological and oncological domain expertise, market-leading technology, and global field experience.
Enhanced patient enrollment and site reliability
Established with an oncology Phase 1 site network and highly qualified site staff, versed in the complexities of early phase study protocols to engage patients, accelerate your time to first patient, and ensure that the right patients are at the right sites in your early phase oncology trial.
Efficient delivery and effective utilisation of data
From real time access, to data visualisation, ICON’s exclusive and intuitive data solutions support the variability and speed needed specifically in early phase projects. Find rapid insights to answer critical study questions, identify trends and outliers, and make better informed decisions with these data resources.
Access to robust bioanalytical services
ICON offers comprehensive bioanalytical services, including laboratory facilities, method development, and specimen analysis for small and large molecule oncology therapeutics.
Oncology insights
ICON's oncology experts provide analysis including whitepapers, blogs and contributions to media and industry conversations relating to all aspects of oncology in clinical trials.
In this section
- Biosimilars
-
Cardiovascular
- Cell and Gene Therapies
- Central Nervous System
- Endocrine & Metabolic Disorders
- Infectious Diseases
- Internal Medicine & Immunology
-
Medical Device
- Oncology
-
Pediatrics
- Rare & Orphan Diseases
- Vaccines
-
Women's Health
-
Therapeutics insights
- Cardiovascular
- Cell and Gene Therapies
- Central Nervous System
-
Glycomics
- Infectious Diseases
- NASH
-
Women's Health Insights
-
Oncology
- Pediatrics
-
Rare and orphan diseases
-
Pushing boundaries in idiopathic pulmonary fibrosis clinical research
-
Advanced therapies for rare diseases
-
Cross-border enrollment of rare disease patients
-
Crossing the finish line: Why effective participation support strategy is critical to trial efficiency and success in rare diseases
-
Diversity, equity and inclusion in rare disease clinical trials
-
Identify and mitigate risks to rare disease clinical programmes
-
Leveraging historical data for use in rare disease trials
-
Natural history studies to improve drug development in rare diseases
-
Patient Centricity in Orphan Drug Development
-
The key to remarkable rare disease registries
-
Pushing boundaries in idiopathic pulmonary fibrosis clinical research